YI insider trading

NasdaqGM Healthcare

111, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
58
Last 90 days
47
Buys / sells
0% / 43%
Market cap
$47.86M

About 111, Inc.

111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides drugs, nutritional supplements, medical supplies and devices, personal care, and baby products. In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool, as well as online consultation, e-prescription, and data services. Further, its pharmacies provide drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies, medical professionals, and marketplace sellers. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.

Company website: corporate.111.com.cn

YI insider activity at a glance

FilingIQ has scored 58 insider transactions for YI since Sep 12, 2018. The most recent filing in our index is dated Jun 15, 2026.

Across the full history, 0 open-market purchases and 25 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on YI insider trades is 57.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Other Healthcare tickers with recent insider activity

Frequently asked

How many insider trades does FilingIQ track for YI?
FilingIQ tracks 58 Form 4 insider transactions for YI (111, Inc.), covering filings from Sep 12, 2018 onwards. 47 of those were filed in the last 90 days.
Are YI insiders net buyers or net sellers?
Across the full Form 4 history for YI, 0 transactions (0%) were open-market purchases and 25 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does YI insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is YI in?
111, Inc. (YI) is classified in the Healthcare sector, specifically Medical Distribution, with a current market capitalisation of $47.86M.

Methodology & sources

Every YI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.